Key facts
- It has raised $615.6M; the latest was Early Stage VC ($615.6M) in Apr 2025.
- Notable investors include Oriental Fortune Capital, Wuxi Capital, Zhongguancun Development Venture Capital Fund, Yinxinggu Capital, BeOne Medicines — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Recorna
- ·The full record, as it builds
Funding rounds
No funding rounds for Recorna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Recorna
Manufacturer of RNA editing-based therapeutic drugs designed to address unmet clinical needs across complex diseases. The company offers proprietary RNA editing platforms and targeted RNA therapeutics with strong safety and efficacy profiles, enabling patients with rare genetic disorders, neurological conditions, and chronic diseases to access new treatment options beyond conventional treatments. targeting RNA editing cutting-edge technologies, enabling patients with RNA drugs.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2021
- Website
- recornabio.com/
- Ownership
- Privately Held (backing)
Recorna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Recorna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Recorna in its N-PORT filings yet. We sweep new filings monthly.